Losartan Effects on Emphysema Progression (LEEP), V2

This research is being done to see if a medicine used to treat high blood pressure, Losartan, can slow the damage to the lungs in people who have COPD with emphysema. Currently, there are some medications for COPD to reduce symptoms and prevent exacerbations. However, there are no treatments to slow or stop the progression of the disease.

Study phase: IV

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

• Are at least 40 years old • Have mild to severe COPD with emphysema • Are a current or former smoker

Additional information:

LEEP is a 52-week (1 year) study. There will be 7 clinic visits at 6 to 12 week intervals. Study visits will take from 1.5 - 4 hours. Procedures at these study visits will include:
• Questionnaires and follow-up assessments about your COPD, breathing, general health, and medical history • A HRCT scan at the first and last visit • A lung function test (spirometry) at the first, last, and one other visit • A physical exam at the first, last, and one other visit • Collecting blood at the first, last, and one other visit • Adjustment of dose from 1 to 2 capsules per day at the third visit only

Primary disease category: Asthma & Lung

Sponsor: National Institue of Health/National Heart, Lung, and Blood Institute

Projected enrollment dates: January 2017 to February 2018

Official study title: Losartan Effects on Emphysema Progression (LEEP), V2